Our results suggest that targeting the COASY/CoA/Succinyl-CoA axis in MDS patients with SF3B1 mutation could represent a highly relevant strategy to treat ineffective erythropoiesis. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.